CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) has announced that the company and the company’s ongoing trial of its investigational Neuro-Spinal Scaffold in patients with acute thoracic spinal cord injury were featured in a front page article in The Boston Globe on Sunday, August 23. The article was published on the front page of The Boston Globe’s website (www.bostonglobe.com) on Friday, August 21. The story was produced by Stat, a new national publication from Boston Globe Media Partners that will launch this fall with coverage of health, medicine, and life sciences. The Boston Globe reaches over 4 million people per month between its online and print content.
“We are pleased to be featured in such a highly regarded media outlet. The progress in our Neuro-Spinal Scaffold clinical development program has been exciting and rewarding, and the role of social media has certainly been a reflection of these dynamics,” said Mark Perrin, InVivo’s Chief Executive Officer and Chairman.
About the Neuro-Spinal Scaffold
Following an acute spinal cord injury, the biodegradable Neuro-Spinal Scaffold is surgically implanted at the epicenter of the wound and is designed to act as a physical substrate for nerve sprouting. Appositional healing to spare spinal cord tissue, decreased post-traumatic cyst formation, and decreased spinal cord tissue pressure have been demonstrated in preclinical models of spinal cord contusion injury. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and is currently being studied in an Investigational Device Exemption (IDE) pilot study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.